Novavax plans to seek emergency authorization from the Food and Drug Administration for its new COVID-19 booster. The booster will be available to people who received two doses of the Novavax vaccine as well as those who were fully vaccinated with another vaccine. (Axios)

In a Phase III trial, Gilead Sciences’ metastatic breast cancer treatment Trodelvy showed “clinically meaningful” results in improving survival, the company said Monday. Among HR+/HER2- metastatic disease patients, the five-year survival rate is currently 30%. (Endpoints News)

Brainstorm will seek FDA approval for its experimental ALS treatment NurOwn. The move comes after the agency stated last year that the therapy doesn’t have enough data supporting its efficacy. (STAT)

People suffering from long COVID are calling on governments to provide more support. There are now approximately 90 long COVID groups in 34 countries. (Politico)

The federal government’s monkeypox vaccination effort has been burdened by delays and missteps, leading to slow distribution of Jynneos. “Our response is completely inefficient and breaking the back of state and local respondents,” said Claire Hannan, executive director of the Association of Immunization Managers. (The New York Times)